Explore the vast range of titles available.

This study examined the influence of player position and match quarter on activity profiles during the phases of play in Australian Football. Global positioning satellite data was collected for one season from an Australian Football League team for nomadic, key position and ruck players (age: 24.8 ± 4.2 years, body mass: 88.3 ± 8.7 kg, height: 1.88 ± 0.8 m). Separate linear mixed models and effect sizes were used to analyse differences between positions and game quarter within each phase of play for values of distance, speed and metabolic power indices. There were clear differences between positions for low-speed running, high-speed running, total distance and average speed. Nomadic players generally recorded the highest match running outputs, followed by key position players and ruckmen. Within each position, offence and defence involved the highest intensities, followed by contested play and then stoppage periods. Across the four quarters, there were small to large reductions in average speed, high-speed running, high power and energy expenditure during offence, defence and contested play, but not during stoppages. Accordingly, conditioning staff should consider the intermittent intensities of the phases of match-play for each position to optimally prepare players for competition. Reductions in match intensities were evident during active periods of play providing implications for real-time monitoring to optimise the timing of rotations.

Since higher vertical stiffness is related to superior athletic performance, training has traditionally been aimed at augmenting this variable to enhance neuromuscular output. However, research has linked elevated stiffness with increased injury risk, therefore, this study examined the effect of a novel training intervention on vertical stiffness and athletic performance. Vertical stiffness, jump performance and athletic performance were assessed in two randomly allocated groups, prior to, and following, an eight-week period. One group was exposed to a training intervention involving aqua-based plyometrics (n = 11) over the 8 weeks while the other acted as a control group (n = 9). The training intervention involved hopping, jumping and bounding in water at a depth of 1.2m whilst control participants performed their normal training. There were no significant changes in vertical stiffness in either group. Countermovement jump height and peak power significantly increased within the aqua plyometric group (p < 0.05). Athletic performance markers improved in the aqua plyometric group as measured using an agility and a 5-bound test exhibiting superior values at the post-test (p < 0.05). The results suggest that an aqua plyometric training program can enhance athletic performance without elevating stiffness. The increase in athletic performance is likely due to a reduction in ground reaction forces created by the buoyancy of the water, causing a shorter amortization phase and a more rapid application of concentric force. The findings from this study can inform exercise professionals and medical staff regarding the ability to enhance neuromuscular performance without elevating vertical stiffness. This has implications for improving athletic performance while concurrently minimising injury risk.

Reducing the dimensionality of commonly reported complex network characteristics obtained from Australian Football League (AFL) games to facilitate their practical use and interpretability. Retrospective longitudinal design where individual players’ interactions, determined through the distribution and receipt of kicks and handballs, during official AFL games were collected over three seasons. A principal component analysis was used to reduce the number of characteristics related to the cooperative network analysis. The principal component analysis derived two individual-based principal components pertaining to in- and out-degree importance and three team-based principal components related to connectedness and in- and out-degree centralisation. This study is the first to provide a simplified, novel method for analysing complex network structures in an Australian Football context with both the team- and individual-derived metrics revealing useful information for coaches and practitioners. This may consequently guide opposition analysis, training implementation, player performance ratings and player selection.

This study aimed to provide a simplified, novel method for analysing technical skill involvements in an Australian Football context by reducing the dimensionality of commonly reported skill counts obtained from Australian Football League (AFL) games. This may facilitate their practical use and interpretability. Retrospective longitudinal design where individual players’ technical skill counts were collected over three seasons of official AFL games. Seventy-three skill count values provided publicly by ChampionData® were collected for each match over a three-year analysis period. A principal component analysis was used to reduce the dimensionality of a large number of correlated technical skill indicators into a smaller set of uncorrelated components whilst maintaining most of the variance from the original data set. The principal component analysis derived four principal components pertaining to high-pressure success, low-pressure success, attacking ball movement ability and scoring ability. This study is the first to provide a simplified, novel method for analysing technical skill counts in Australian Football. The derived metrics reveal useful information for coaches and practitioners. This may consequently ease the interpretation of skill count data available to coaches from games, guide opposition analysis, help in the design of representative practice and inform player performance ratings.

Black and Hispanic children living in urban environments in the USA have an excess burden of morbidity and mortality from asthma. Therapies directed at the eosinophilic phenotype reduce asthma exacerbations in adults, but few data are available in children and diverse populations. Furthermore, the molecular mechanisms that underlie exacerbations either being prevented by, or persisting despite, immune-based therapies are not well understood. We aimed to determine whether mepolizumab, added to guidelines-based care, reduced the number of asthma exacerbations during a 52-week period compared with guidelines-based care alone. This is a randomised, double-blind, placebo-controlled, parallel-group trial done at nine urban medical centres in the USA. Children and adolescents aged 6–17 years, who lived in socioeconomically disadvantaged neighbourhoods and had exacerbation-prone asthma (defined as ≥two exacerbations in the previous year) and blood eosinophils of at least 150 cells per μL were randomly assigned 1:1 to mepolizumab (6–11 years: 40 mg; 12–17 years: 100 mg) or placebo injections once every 4 weeks, plus guideline-based care, for 52 weeks. Randomisation was done using a validated automated system. Participants, investigators, and the research staff who collected outcome measures remained masked to group assignments. The primary outcome was the number of asthma exacerbations that were treated with systemic corticosteroids during 52 weeks in the intention-to-treat population. The mechanisms of treatment response were assessed by study investigators using nasal transcriptomic modular analysis. Safety was assessed in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03292588. Between Nov 1, 2017, and Mar 12, 2020, we recruited 585 children and adolescents. We screened 390 individuals, of whom 335 met the inclusion criteria and were enrolled. 290 met the randomisation criteria, were randomly assigned to mepolizumab (n=146) or placebo (n=144), and were included in the intention-to-treat analysis. 248 completed the study. The mean number of asthma exacerbations within the 52-week study period was 0·96 (95% CI 0·78–1·17) with mepolizumab and 1·30 (1·08–1·57) with placebo (rate ratio 0·73; 0·56–0·96; p=0·027). Treatment-emergent adverse events occurred in 42 (29%) of 146 participants in the mepolizumab group versus 16 (11%) of 144 participants in the placebo group. No deaths were attributed to mepolizumab. Phenotype-directed therapy with mepolizumab in urban children with exacerbation-prone eosinophilic asthma reduced the number of exacerbations. US National Institute of Allergy and Infectious Diseases and GlaxoSmithKline.

Streams play a key role in the global carbon cycle. The balance between carbon intake through photosynthesis and carbon release via respiration influences carbon emissions from streams and depends on temperature. However, the lack of a comprehensive analysis of the temperature sensitivity of the metabolic balance in inland waters across latitudes and local climate conditions hinders an accurate projection of carbon emissions in a warmer future. Here, we use a model of diel dissolved oxygen dynamics, combined with high-frequency measurements of dissolved oxygen, light and temperature, to estimate the temperature sensitivities of gross primary production and ecosystem respiration in streams across six biomes, from the tropics to the arctic tundra. We find that the change in metabolic balance, that is, the ratio of gross primary production to ecosystem respiration, is a function of stream temperature and current metabolic balance. Applying this relationship to the global compilation of stream metabolism data, we find that a 1 °C increase in stream temperature leads to a convergence of metabolic balance and to a 23.6% overall decline in net ecosystem productivity across the streams studied. We suggest that if the relationship holds for similarly sized streams around the globe, the warming-induced shifts in metabolic balance will result in an increase of 0.0194 Pg carbon emitted from such streams every year.

Background The Cancer Genome Atlas analysis revealed that somatic EGFR , receptor tyrosine-protein kinase erbB-2 ( ERBB2 ), Erb-B2 receptor tyrosine kinase 3 ( ERBB3 ) and Erb-B2 receptor tyrosine kinase 4 ( ERBB4 ) gene mutations (ERBB family mutations) occur alone or co-occur with somatic mutations in the gene encoding the phosphatidylinositol 3-kinase (PI3K) catalytic subunit ( PIK3CA ) in 19% of human epidermal growth factor receptor 2 (HER2)-positive breast cancers. Because ERBB family mutations can activate the PI3K/AKT pathway and likely have similar canonical signalling effects to PI3K pathway mutations, we investigated their combined impact on response to neoadjuvant HER2-targeted therapies. Methods Baseline tumour biopsies were available from 74 patients with HER2-positive breast cancer who were enrolled in the phase II TCHL neoadjuvant study (ICORG 10-05) assessing TCH (docetaxel, carboplatin, trastuzumab) ( n  = 38) versus TCL (docetaxel, carboplatin, lapatinib) ( n  = 10) versus TCHL (docetaxel, carboplatin, trastuzumab, lapatinib) ( n  = 40), each for six cycles. Activating mutations in PIK3CA and ERBB family genes were identified using mass spectrometry-based genotyping. Phosphatase and tensin homolog (PTEN) expression was assessed by immunohistochemistry. Results PIK3CA and/or ERBB family mutations were detected in 23 (31.1%) tumour samples tested, whereas PTEN expression was low in 31.1% of cases tested. Mutation frequency was similar in each treatment arm (31.3% in TCH arm, 30% in TCL arm and 31.3% in TCHL arm) and was not influenced by oestrogen receptor (ER) status (27.6% in ER-negative patients, 33.3% in ER-positive patients) or progesterone receptor (PR) status (32.6% in PR-negative patients, 29% in PR-positive patients). There was no significant difference in pathological complete response (pCR) rates between 47 patients with wild-type (WT) tumours and 22 patients whose tumours carried mutations (in either PIK3CA or ERBB family genes) (42.5% vs. 54.5%; p  = 0.439). Similarly, there was no significant difference in pCR rates between patients with PIK3CA/ERBB family mutated/PTEN-low (i.e., PI3K-activated) tumours and patients without PI3K activation (50% vs. 44%; p  = 0.769). However, in the TCHL (but not the TCH) group, the pCR rate was higher for 9 patients with PIK3CA/ERBB family mutated tumours than for 20 patients with PIK3CA/ERBB family WT tumours (77.8% vs. 35%; p  = 0.05). Conclusions Our results indicate that patients who receive neoadjuvant TCHL and have PIK3CA/ERBB family mutated tumours may be more likely to have a pCR than patients with WT tumours. Trial registration ClinicalTrials.gov, NCT01485926 . Registered on 2 December 2011.

Inhaled glucocorticoids may prevent a mild loss of asthma control from becoming a full exacerbation. In a randomized trial involving children, quintupling the daily dose at early signs of loss of asthma control did not result in a lower rate of severe asthma exacerbations. Increases in symptoms may occur before exacerbations fully develop. In two trials, when symptoms occurred, the dose of inhaled glucocorticoids was increased by a factor of 5 (pediatric trial) or 4 (adult trial). There was no benefit, and perhaps some harm, in children, and a modest benefit in adults.

There has been concern that acetaminophen may exacerbate asthma. These investigators found no difference in asthma control among young children treated for minor illnesses with acetaminophen as compared with ibuprofen. Many children younger than 12 years of age receive acetaminophen each week, making it the most commonly used pediatric medication in the United States. 1 Observational data from both pediatric and adult cohorts have suggested an association between acetaminophen use and concurrent asthma symptoms and decreased lung function. 2 – 6 Furthermore, a post hoc analysis of a randomized trial on the safety of short-term use of acetaminophen versus ibuprofen for febrile illnesses in children similarly showed that the relative risk of unscheduled visits for asthma after the use of acetaminophen was substantially higher than the risk after the use of ibuprofen. 7 These . . .